Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Sang-Eun | - |
dc.contributor.author | Brignone, Melanie | - |
dc.contributor.author | Cho, Seong Jin | - |
dc.contributor.author | Jeon, Hong Jin | - |
dc.contributor.author | Jung, Rangrhee | - |
dc.contributor.author | Campbell, Rosanne | - |
dc.contributor.author | Francois, Clement | - |
dc.contributor.author | Milea, Dominique | - |
dc.date.accessioned | 2021-09-03T19:13:52Z | - |
dc.date.available | 2021-09-03T19:13:52Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-10 | - |
dc.identifier.issn | 1473-7167 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87310 | - |
dc.description.abstract | Objective: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea.Methods: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states.Results: Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations.Conclusion: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | STAR-ASTERISK-D | - |
dc.subject | SUICIDAL IDEATION | - |
dc.subject | ANTIDEPRESSANTS | - |
dc.subject | PREVALENCE | - |
dc.subject | OUTCOMES | - |
dc.subject | SINGLE | - |
dc.subject | ADULTS | - |
dc.subject | MODEL | - |
dc.title | Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Sang-Eun | - |
dc.identifier.doi | 10.1586/14737167.2016.1128830 | - |
dc.identifier.scopusid | 2-s2.0-84954229358 | - |
dc.identifier.wosid | 000385942500010 | - |
dc.identifier.bibliographicCitation | EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, v.16, no.5, pp.629 - 638 | - |
dc.relation.isPartOf | EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | - |
dc.citation.title | EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 629 | - |
dc.citation.endPage | 638 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Policy & Services | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | STAR-ASTERISK-D | - |
dc.subject.keywordPlus | SUICIDAL IDEATION | - |
dc.subject.keywordPlus | ANTIDEPRESSANTS | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | SINGLE | - |
dc.subject.keywordPlus | ADULTS | - |
dc.subject.keywordPlus | MODEL | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | antidepressant | - |
dc.subject.keywordAuthor | cost-effectiveness | - |
dc.subject.keywordAuthor | economic | - |
dc.subject.keywordAuthor | model | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.